April 20, 2023 – BeiGene, Novartis’ tislelizumab stages comeback with broader stomach cancer trial win
When BeiGene and Novartis announced a partial trial win for tislelizumab in stomach cancer, doubts started to circulate around the PD-1 inhibitor’s potential. Now, the partners have come back with broader success.
Tislelizumab’s ability to extend lives in newly diagnosed advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma now covers all patients with or without PD-L1 expression in their tumors, BeiGene said Thursday.
← April 17, 2023 – Innovent Releases Final Analysis Results of ORIENT-16: the Phase 3 Study of Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric Cancer at the AACR Annual Meeting 2023April 21, 2023 – Zolbetuximab/mFOLFOX6 Prolongs Survival in Locally Advanced Gastric Cancer →